Stephanie Jordaens

Ms. Stephanie Jordaens

University of Antwerp, Antwerp, Flanders, Belgium
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 January 2023 in International Journal of Cancer
Verified
Journal Article
Open access
Stephanie JordaensStephanie Jordaens
Stephanie Jordaens
UAUniveristy of Antwerp
Univeristy of Antwerp
WTWiebren Tjalma
Wiebren Tjalma
CDChristophe Deben
Christophe Deben
KBKoen Beyers
Koen Beyers
AVAlex Vorsters
Alex Vorsters
The aim of this review was to explore the status of urine sampling as a liquid biopsy for noninvasive cancer research by reviewing used preanalytical parameters and protocols. We searched two main health sciences databases, PubMed and Web of Science. From all eligible publications (2010‐2022), information was extracted regarding: (a) study population characteristics, (b) cancer type, (c) urine preanalytics, (d) analyte class, (e) isolation method, (f) detection method, (g) comparator used, (h) biomarker type, (i) conclusion and (j) sensitivity and specificity. The search query identified 7835 records, of which 924 unique publications remained after screening the title, abstract and full text. Our analysis demonstrated that many publications did not report information about the preanalytical parameters of their urine samples, even though several other studies have shown the importance of standardization of sample handling. Interestingly, it was noted that urine is used for many cancer types and not just cancers originating from the urogenital tract. Many different types of relevant analytes have been shown to be found in urine. Additionally, future considerations and recommendations are discussed: (a) the heterogeneous nature of urine, (b) the need for standardized practice protocols and (c) the road toward the clinic. Urine is an emerging liquid biopsy with broad applicability in different analytes and several cancer types. However, standard practice protocols for sample handling and processing would help to elaborate the clinical utility of urine in cancer research, detection and disease monitoring.

2 April 2021 in Cancers
Verified
Journal Article
Open access
PDF file
EAElien Augustus
Elien Augustus
UAUniveristy of Antwerp
Univeristy of Antwerp
VSVasiliki Siozopoulou
Vasiliki Siozopoulou
JRJo Raskin
Jo Raskin
Stephanie JordaensStephanie Jordaens
Stephanie Jordaens
Patrick PauwelsPatrick Pauwels
Patrick Pauwels
In the last decade, immunotherapy has been one of the most important advances in the non-small cell lung cancer (NSCLC) treatment landscape. Nevertheless, only a subset of NSCLC patients benefits from it. Currently, the only Food and Drug Administration (FDA) approved diagnostic test for first-line immunotherapy in metastatic NSCLC patients uses tissue biopsies to determine the programmed death ligand 1 (PD-L1) status. However, obtaining tumor tissue is not always feasible and puts the patient at risk. Liquid biopsy, which refers to the tumor-derived material present in body fluids, offers an alternative approach. This less invasive technique gives real-time information on the tumor characteristics. This review addresses different promising liquid biopsy based biomarkers in NSCLC patients that enable the selection of patients who benefit from immunotherapy and the monitoring of patients during this therapy. The challenges and the opportunities of blood-based biomarkers such as cell-free DNA (cfDNA), circulating tumor cells (CTCs), exosomes, epigenetic signatures, microRNAs (miRNAs) and the T cell repertoire will be addressed. This review also focuses on the less-studied feces-based and breath-based biomarkers.

1 June 2023 in Biomolecules
Verified
Journal Article
Open access
PDF file
Stephanie JordaensStephanie Jordaens
Stephanie Jordaens
EOEline Oeyen
Eline Oeyen
HWHanny Willems
Hanny Willems
FAFilip Ameye
Filip Ameye
SWStefan De Wachter
Stefan De Wachter
IMInge Mertens
Inge Mertens
Urinary extracellular vesicles (EVs) are an attractive source of bladder cancer biomarkers. Here, a protein biomarker discovery study was performed on the protein content of small urinary EVs (sEVs) to identify possible biomarkers for the primary diagnosis and recurrence of non-muscle-invasive bladder cancer (NMIBC). The sEVs were isolated by ultrafiltration (UF) in combination with size-exclusion chromatography (SEC). The first part of the study compared healthy individuals with NMIBC patients with a primary diagnosis. The second part compared tumor-free patients with patients with a recurrent NMIBC diagnosis. The separated sEVs were in the size range of 40 to 200 nm. Based on manually curated high quality mass spectrometry (MS) data, the statistical analysis revealed 69 proteins that were differentially expressed in these sEV fractions of patients with a first bladder cancer tumor vs. an age- and gender-matched healthy control group. When the discriminating power between healthy individuals and first diagnosis patients is taken into account, the biomarkers with the most potential are MASP2, C3, A2M, CHMP2A and NHE-RF1. Additionally, two proteins (HBB and HBA1) were differentially expressed between bladder cancer patients with a recurrent diagnosis vs. tumor-free samples of bladder cancer patients, but their biological relevance is very limited.

8 June 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Stephanie JordaensStephanie Jordaens
Stephanie Jordaens
AAAmit Arora
Amit Arora
KMKyle W. MacDonald
Kyle W. MacDonald
CWCameron Wood
Cameron Wood
JHJhana O. Hendrickx
Jhana O. Hendrickx
VVVanessa Vankerckhoven
Vanessa Vankerckhoven
Liquid biopsy is a revolutionary tool that is gaining momentum in the field of cancer research. As a body fluid, urine can be used in non-invasive diagnostics for various types of cancer. We investigated the performance of UAS™ as a preservative for urinary analytes. Firstly, the need for urine preservation was investigated using urine samples from healthy volunteers. Secondly, the performance of UAS™ was assessed for cell-free DNA (cfDNA) and host cell integrity during storage at room temperature (RT) and after freeze-thaw cycling. Finally, UAS™ was used in a clinical setting on samples from breast and prostate cancer patients. In the absence of a preservative, urinary cfDNA was degraded, and bacterial overgrowth occurred at RT. In urine samples stored in UAS™, no microbial growth was seen, and cfDNA and cellular integrity were maintained for up to 14 days at RT. After freeze-thaw cycling, the preservation of host cell integrity and cfDNA showed significant improvements when using UAS™ compared to unpreserved urine samples. Additionally, UAS™ was found to be compatible with several commercially available isolation methods.

1 May 2020 in British Journal of Haematology
Verified
Journal Article
Closed access
PDF file
Stephanie JordaensStephanie Jordaens
Stephanie Jordaens
LCLeah Cooksey
Leah Cooksey
SBStephanie Bonney
Stephanie Bonney
LOLaurence Orchard
Laurence Orchard
MCMatthew Coutinho
Matthew Coutinho
Barbara-ann GuinnBarbara-ann Guinn
Barbara-ann Guinn

22 January 2020 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
Stephanie JordaensStephanie Jordaens
Stephanie Jordaens
LCLeah Cooksey
Leah Cooksey
LBLaurie Freire Boullosa
Laurie Freire Boullosa
VTViggo Van Tendeloo
Viggo Van Tendeloo
ESEvelien Smits
Evelien Smits
Barbara-ann GuinnBarbara-ann Guinn
Barbara-ann Guinn
Acute lymphoblastic leukaemia (ALL) in adults is a rare and difficult-to-treat cancer that is characterised by excess lymphoblasts in the bone marrow. Although many patients achieve remission with chemotherapy, relapse rates are high and the associated impact on survival devastating. Most patients receive chemotherapy and for those whose overall fitness supports it, the most effective treatment to date is allogeneic stem cell transplant that can improve overall survival rates in part due to a ‘graft-versus-leukaemia’ effect. However, due to the rarity of this disease, and the availability of mature B-cell antigens on the cell surface, few new cancer antigens have been identified in adult B-ALL that could act as targets to remove residual disease in first remission or provide alternative targets for escape variants if and when current immunotherapy strategies fail. We have used RT-PCR analysis, literature searches, antibody-specific profiling and gene expression microarray analysis to identify and prioritise antigens as novel targets for the treatment of adult B-ALL.